← All trials
NCT04204889
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jan 31, 2020
- Primary completion
- Jan 31, 2021
- Completion date
- Feb 28, 2021
- First posted
- —
- Last posted
- —
- Enrollment
- 24
- Arms / groups
- 1 / —
- Source
- AACT · ingestion pipeline
Sponsors
- University of KansasLead sponsor
- University of KansasOverall official - principal investigator
- University of KansasSponsor investigator
- Terra Biological LLCCollaborator
- Rare Diseases Clinical Research NetworkCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.